Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Metabolix, Inc. (NASDAQ:MBLX - News), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today announced it has hired three new senior leaders to support the company's chemicals and crops programs. Sharie Fitzpatrick joins Metabolix as Director of Crop Regulatory Affairs, Max Senechal was named Director of Strategy, and Dr. Siva Sivasubramanian has been appointed Director of Process Technology. All three will report to Johan van Walsem, Vice President of Strategy and Commercial Development at Metabolix.

"These additions to our Commercial and Strategic Development group represent an important step in the growth of Metabolix," said Richard Eno, President and CEO of Metabolix. "Accelerating the commercialization of our fermentation chemicals and crops programs requires skilled and experienced personnel. We are confident that Sharie, Max and Siva will bring strong contributions to our team as we deliver innovative fermentation chemicals and crop-based solutions to the rapidly growing marketplace for biobased materials."

Sharie Fitzpatrick – Director of Crop Regulatory Affairs

In her role as Director of Crop Regulatory Affairs, Fitzpatrick will be responsible for working with the U.S. Department of Agriculture and other regulatory organizations on the commercialization of Metabolix's crop programs.

Fitzpatrick joins Metabolix after more than 15 years with Forage Genetics International, a wholly owned subsidiary of Land O'Lakes, Inc., most recently serving as director of regulatory affairs and seed quality assurance for Biotech Traits. In that role, Fitzpatrick led the company's biotech trait alfalfa event selection, trait integration, permit compliance, regulatory clearances and commercial trait stewardship efforts. She also participated closely in the U.S. and global development of the first biotech trait alfalfa.

Prior to her work at Forage Genetics, Fitzpatrick served as the manager of alfalfa plant pathology and plant tissue culture at WL Research, Inc., and as a research scientist in plant pathology at the University of Wisconsin. She earned a bachelor's degree and M.S. in Natural Sciences and Plant Pathology, respectively, from the University of Wisconsin.

Max Senechal – Director of Strategy

As Director of Strategy, Senechal will be instrumental in developing the strategic direction and commercialization path for the Metabolix fermentation chemicals and crop-based plastics and chemicals businesses. He will work closely with the Metabolix technology and commercial teams, ensuring organizational priorities are aligned with the strategic direction and commercialization path. He will also be responsible for identification and development of business partnerships.

For nearly a decade, Senechal served in various roles including vice president of the chemicals, petroleum and life sciences practices at Charles River Associates (CRA), a Boston-based management consulting firm. Prior to joining CRA, Senechal was a senior manager with Arthur D. Little's (ADL) global chemicals practice. During his tenures at CRA and ADL, Senechal focused on strategy and operations management issues for leading global chemicals and industrial companies, providing advice on matters of corporate, business unit and technology strategy, as well as M&A and performance improvement.

Senechal also has experience supervising the design, construction and start-up of industrial facilities in several industries, including commodity, specialty and fine chemicals. He earned an MBA from the University of Massachusetts and a bachelor's degree in Mechanical Engineering from Laval University in Quebec, Canada.

Dr. Siva Sivasubramanian – Director of Process Technology

As Director of Process Technology, Dr. Sivasubramanian will spearhead the company's efforts aimed at development and scale-up of industry leading process technologies for cost-competitive production of the Metabolix fermentation chemicals and crop-based plastics and chemicals.

Sivasubramanian has more than 24 years of technical expertise in technology and process development. Before joining Metabolix, he was the vice president of engineering at Mascoma Corporation. Prior to Mascoma, Sivasubramanian spent 14 years with Aspen Technology, Inc., where his expertise included leading engineering designs, the scaling-up of processes from concept to commercial designs, and the development of software to simulate and design separation process operations such as distillation, absorption and stripping systems. Sivasubramanian has also consulted for a number of international companies in the area of separation processes. He earned M.S. and Ph.D. degrees in Chemical Engineering from Clarkson University in Potsdam, NY.

"Sharie, Max and Siva bring nearly a half century's worth of highly relevant commercial development and industrial experience to Metabolix," said van Walsem. "Their depth and breadth of experience in regulatory affairs, strategy and process development makes them invaluable members of our commercialization team, and we look forward to their involvement as we continue to expand our chemical and crop portfolios."

About Metabolix

Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel&#8482, a family of high performance bioplastics which are biobased and biodegradable alternatives to many petroleum based plastics. Metabolix is also developing a proprietary platform technology for co-producing plastics, chemicals and energy, from crops such as switchgrass, oilseeds and sugarcane.

For more information, please visit www.metabolix.com. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for Metabolix research and development, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Media:
Schwartz Communications
Keith Giannini or Jen Barlow, 781-684-0770
metabolix@schwartzcomm.com
or
Investors:
ICR
James Palczynski, 203-682-8229
james.palczynski@icrinc.com